大肠癌术中植入氟尿嘧啶缓释剂安全性及其临床疗效的研究

目的探讨大肠癌术中植入氟尿嘧啶（5-Fu）缓释剂的安全性及其临床疗效。方法158例直肠癌患者被随机分为A（植入组）、B（腹腔灌注组）和c（对照组）3组，A组采用手术＋术中腹腔植入氟尿嘧啶缓释剂；B组采用手术＋腹腔热灌注化疗；C组采用传统手术＋化疗。比较3组术后并发症和首次化疗毒性反应以及3组2、5年生存率。结果A组和B组并发症相当，对骨髓抑制和肝脏功能损害较C组轻；无论在2年还是5年无瘤生存率和总生存率A和B组差异无统计学意义，但是2年无病生存率均较C组高，差异具有统计学意义（P〈0．05）；3组在2年生存率、5年总无瘤生存率和5年总生存率均差异无统计学意义。结论大肠癌术中植入氟尿嘧啶缓释剂安全可靠，能降低2年复发率，但并不能提高近期和远期生存率。

Safety and its clinical curative effect of intra abdominal implantation of sustained releasing fluorouracil in patients with colorectal cancer

Objective To study the safety and its clinical curative effect of intra abdominal implantation of sustained releasing fluorouracil. Methods One hundred and fifty-eight patients in the Department of First Pathology confirmed as II/III stage colorectal cancer were randomly divided into three groups, A （implantation group）, B （celiac infusion group） and C （control group）. Group A was given radical surgical operation ＋ intra abdominal implantation of sustained releasing fluorouracil; Group B radical surgical operation ＋ celiac hot infusion chemotherapy; Group C radical surgery ＋ traditional chemotherapy. The postoperative complications, first chemotherapy toxicity, 2-year and 5-year survival rate of the three groups were compared respectively. Results There were equivalent complications in Group A and B, their bone marrow suppression and liver function damage were lighter than Group C. There were no significant differences between the 2-year or 5-year disease-free and overall survival rate of Group A and B, but the disease-free survival rates of Group A and B were higher than that of Group C, with statistical significance, /0〈0.05. Three groups showed no significant difference in the 2-year overall survival rate, disease-free survival rate of 5-year and 5-year overall survival rate. Conclusion Intra abdominal implantation of sustained releasing fluorouracil is safe; it may reduce the 2-year recurrence, but can not improve immediate and long-term survival rate.